Antimalarial activity of the anticancer histone deacetylase inhibitor SB939

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3849-3856

  Sumanadasa, Subathdrage D M ^a,b   Goodman, Christopher D ^c   Lucke, Andrew J ^d   Skinner Adams, Tina ^b   Saham, Ishani ^b,d   Haque, Ashraful ^b   Do, Tram Anh ^d   McFadden, Geoffrey I ^c   Fairlie, David P ^d   Andrews, Katherine T ^a,b  

^a GRIFFITH UNIVERSITY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 BUTYL 1 [2 (DIETHYLAMINO)ETHYLBENZIMIDAZOL 5 YL]PROP 2 ENE HYDROXAMIC ACID; ANTIMALARIAL AGENT; CHLOROQUINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; LOPINAVIR; PIPERAQUINE; PRIMAQUINE; SB 939; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; BRAIN MALARIA; CONTROLLED STUDY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SYMPTOM; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CEREBRUM; HISTONE DEACETYLASE INHIBITORS; MALARIA; MICE; PLASMODIUM FALCIPARUM;

EID: 84862571804     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00030-12     Document Type: Article

References (67)

1. Agbor-Enoh S, Seudieu C, Davidson E, Dritschilo A, Jung M. 2009. Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice. Antimicrob. Agents Chemother. 53:1727-1734.
2. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
3. Amante FH, et al. 2007. A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am. J. Pathol. 171:548-559.
4. Andrews KT, et al. 2006. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 50:639-648.
5. Andrews KT, Haque A, Jones MK. 2012. HDAC inhibitors in parasitic diseases. Immunol. Cell Biol. 90:66-77.
6. Andrews KT, et al. 2008. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob. Agents Chemother. 52:1454-1461.
7. Andrews KT, Tran TN, Wheatley NC, Fairlie DP. 2009. Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr. Top. Med. Chem. 9:292-308.
8. Andrews KT, et al. 2000. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int. J. Parasitol. 30:761-768.
9. Aurrecoechea C, et al. 2009. PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res. 37:D539-D543.
10. Bali P, et al. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280:26729-26734.
11. Bates MD, Meshnick SR, Sigler CI, Leland P, Hollingdale MR. 1990. In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei. Am. J. Trop. Med. Hyg. 42:532-537.
12. Berenbaum M. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130.
13. Berendt AR, Tumer GD, Newbold CI. 1994. Cerebral malaria: the sequestration hypothesis. Parasitol. Today 10:412-414.
14. Berman HM, et al. 2000. The Protein Data Bank. Nucleic Acids Res. 28:235-242.
15. Beumer JH, Tawbi H. 2010. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr. Clin. Pharmacol. 5:196-208.
16. Bressi JC, et al. 2010. Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg. Med. Chem. Lett. 20:3142-3145.
17. Cairns BR. 2001. Emerging roles for chromatin remodeling in cancer biology. Trends Cell Biol. 11:S15-S21.
18. Canfield C, Pudney M, Gutteridge W. 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp. Parasitol. 80:373-381.
19. Chaal BK, Gupta AP, Wastuwidyaningtyas BD, Luah YH, Bozdech Z. 2010. Histone deacetylases play a major role in the transcriptional regulation of the Plasmodium falciparum life cycle. PLoS Pathog. 6:e1000737. doi:10.1371/journal. ppat.1000737.
20. Crabb SJ, et al. 2008. Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem. Pharmacol. 76:463-475.
21. Darkin-Rattray SJ, et al. 1996. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. U. S. A. 93: 13143-13147.
22. Dokmanovic M, Clarke C, Marks PA. 2007. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5:981-989.
23. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
24. Dow GS, et al. 2008. Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob. Agents Chemother. 52:3467-3477.
25. Duraisingh MT, et al. 2005. Heterochromatin silencing and locus repositioning linked to regulation of virulence genes in Plasmodium falciparum. Cell 121:13-24.
26. Eisenberg D, Luthy R, Bowie JU. 1997. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 277 :396-404.
27. Finnin MS, et al. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193.
28. Freitas-Junior LH, et al. 2005. Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites. Cell 121:25-36.
29. Gao L, Cueto MA, Asselbergs F, Atadja P. 2002. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277:25748-25755.
30. Glozak MA, Sengupta N, Zhang X, Seto E. 2005. Acetylation and deacetylation of non-histone proteins. Gene 363:15-23.
31. Grozinger CM, Schreiber SL. 2002. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9:3-16.
32. Hu G, et al. 2010. Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum. Nat. Biotechnol. 28:91-98.
33. Huber W, Koella JC. 1993. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop. 55:257-261.
34. Jain AN. 2008. Bias, reporting, and sharing: computational evaluations of docking methods. J. Comput. Aided Mol. Des. 22:201-212.
35. Jayaraman R, et al. 2011. Preclinical metabolism and disposition of SB939 (pracinostat), an orally active histone deacetylase (HDAC) inhibitor, and prediction of human pharmacokinetics. Drug Metab. Dispos. 39:2219-2232.
36. Joshi MB, et al. 1999. Molecular cloning and nuclear localization of a histone deacetylase homologue in Plasmodium falciparum. Mol. Biochem. Parasitol. 99:11-19.
37. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. 2009. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem. 284:7436-7445.
38. Lehrman G, et al. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555.
39. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
40. Ma X, Ezzeldin HH, Diasio RB. 2009. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69:1911-1934.
41. Marfurt J, et al. 2011. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob. Agents Chemother. 55:961-966.
42. Marks PA. 2010. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Invest. Drugs 19:1049-1066.
43. Matalon S, Rasmussen TA, Dinarello CA. 2011. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol. Med. 17:466-472.
44. Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6:38-51.
45. Mok S, et al. 2011. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 12:391. doi:10.1186/1471-2164-12-391.
46. Nair SC, et al. 2011. Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii. J. Exp. Med. 208:1547-1559.
47. Novotny-Diermayr V, et al. 2010. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol. Cancer Ther. 9:642-652.
48. Ortore G, Di Colo F, Martinelli A. 2009. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities. J. Chem. Infect. Model. 49:2774-2785.
49. Pallavi R, et al. 2010. Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J. Biol. Chem. 285:37964-37975.
50. Patel V, et al. 2009. Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. J. Med. Chem. 52:2185-2187.
51. Pradines B, et al. 2006. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob. Agents Chemother. 50:3225-3226.
52. Razak AR, et al. 2011. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br. J. Cancer 104:756-762.
53. Sali A, Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:779-815.
54. Sanderson L, et al. 2004. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. Drug Metab. Dispos. 32:1132-1138.
55. Sarr SO, et al. 2011. Icacina senegalensis (Icacinaceae), traditionally used for the treatment of malaria, inhibits in vitro Plasmodium falciparum growth without host cell toxicity. Malar. J. 10:85.
56. Schmidt-Christensen A, Sturm A, Horstmann S, Heussler VT. 2008. Expression and processing of Plasmodium berghei SERA3 during liver stages. Cell. Microbiol. 10:1723-1734.
57. Shen MY, Sali A. 2006. Statistical potential for assessment and prediction of protein structures. Protein Sci. 15:2507-2524.
58. Skinner-Adams TS, Andrews KT, Melville L, McCarthy J, Gardiner DL. 2007. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 51:759-762.
59. Somoza JR, et al. 2004. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12:1325-1334.
60. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
61. Tonkin CJ, et al. 2009. Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparum. PLoS Biol. 7:e84. doi:10.1371/journal.pbio.1000084.
62. Vennerstrom JL, et al. 1999. 8-Aminoquinolines active against blood-stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob. Agents Chemother. 43:598-602.
63. Wagner JM, Hackanson B, Lubbert M, Jung M. 2010. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenet. 1:117-136.
64. Waller RF, Reed MB, Cowman AF, McFadden GI. 2000. Protein trafficking to the plastid of Plasmodium falciparum is via the secretory pathway. EMBO J. 19:1794-1802.
65. Wang H. 2011. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H- benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J. Med. Chem. 54:4694-4720.
66. WHOCommunicable Diseases Cluster. 2000. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl 1):S1-S90.
67. Yong WP, et al. 2011. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann. Oncol. 22:2516-2522.